Two peptides, one stack, and a lot of internet hype. Here is what the published research actually supports — and where the claims outrun the science.
A modified analog of GHRH (growth hormone releasing hormone). It extends the signaling that tells your pituitary to release growth hormone. Comes in two variants: DAC (Drug Affinity Complex) which binds to albumin and extends the half-life to roughly 6-8 days, and no-DAC (also called Mod GRF 1-29) with a half-life measured in hours. No-DAC produces sharper GH pulses that mimic natural release patterns. DAC creates a sustained, steadier elevation.
A growth hormone secretagogue — it mimics the hunger hormone ghrelin at the GHS receptor, which triggers GH release from a different pathway than CJC-1295. Crucially, Ipamorelin is selective: unlike older secretagogues like GHRP-6, it does not meaningfully raise cortisol or prolactin levels. That selectivity is a genuine pharmacological advantage that separates it from earlier compounds in the same class.
CJC-1295 amplifies the GHRH pathway (the "release more" signal). Ipamorelin amplifies the ghrelin pathway (the "release now" signal). Together, they produce synergistic GH pulse amplification — larger and more frequent pulses than either peptide alone. Think of it as pressing the gas pedal and removing the brake at the same time.
The peptide community, influencers, and paid courses repeat these claims constantly. Some have a kernel of truth. Some are pure marketing.
Teichman et al. (2006, JCEM) demonstrated that CJC-1295 significantly increases growth hormone and IGF-1 levels in healthy adults (n=33). The mechanism is legitimate. Both peptides stimulate GH release through complementary pathways, and the combined effect is additive.
You are boosting your own pituitary output, not replacing it with supraphysiological doses. The GH pulses are larger than baseline but substantially smaller than what 2-4 IU of pharmaceutical HGH delivers. Anyone expecting HGH-level body composition changes from secretagogues is setting themselves up for disappointment.
Growth hormone release is naturally tied to deep sleep (slow-wave sleep). Amplifying GH pulses at night aligns with the body's own rhythm. Improved deep sleep quality is one of the most consistently reported subjective benefits, and the mechanism makes physiological sense. It is not proven in controlled trials specific to this stack, but it is biologically plausible.
Do not expect visible body composition changes in weeks. The magnitude of GH elevation from secretagogues produces modest effects that accumulate over months. Think marginal improvement in recovery, slight shift in fat-to-lean ratio over 3-6 months — not transformative recomposition.
The DAC variant (Drug Affinity Complex) binds to albumin in the blood, extending the half-life to roughly 6-8 days. This means sustained, blunted GH elevation rather than sharp pulses. No-DAC (Mod GRF 1-29) has a half-life of hours and produces the acute pulsatile pattern that more closely mimics natural physiology. Most community protocols favor no-DAC for this reason.
Stimulating your own GH production is not the same as injecting GH, but it is not without effects. Potential issues include water retention, carpal tunnel-like symptoms (tingling in hands), transient cortisol elevation, and the theoretical concern of insulin resistance with sustained IGF-1 elevation. These are dose-dependent and generally mild, but "completely safe" is an overstatement.
Whether the pituitary downregulates its response to continuous GHRH/ghrelin-mimetic stimulation over time is an open question. Some practitioners cycle patients (8-12 weeks on, 4 weeks off). Others run it continuously. No controlled human study has definitively settled the desensitization question for this stack.
These peptides have not gone through Phase III trials for the use cases the community applies them to. Short-term tolerability data exists. Long-term safety data — years of use — does not. This is not a reason to panic, but it is a reason to monitor and to be honest about what we do not know.
Because the goal is to elevate IGF-1 (the downstream marker of GH activity), tracking serum IGF-1 levels gives you objective data on whether the stack is doing anything for you — and whether you are pushing levels higher than intended. Fasting glucose monitoring is also prudent given the insulin-sensitivity concern.
CJC-1295 + Ipamorelin is a reasonable approach to mildly boosting your own growth hormone output. The mechanism is real, the pharmacology makes sense, and the synergistic rationale for stacking them is sound. But anyone expecting HGH-level results from secretagogues is going to be disappointed. Set realistic expectations: potentially better sleep, modest improvements in recovery and body composition over months, and a generally well-tolerated side effect profile. Track your sleep, body composition, and IGF-1 levels over months — not weeks. The data is your answer, not the internet hype.
The foundational human study. Demonstrated dose-dependent GH and IGF-1 increases in 33 healthy adults over multiple weeks. Established that CJC-1295 produces sustained GH elevation with good tolerability.
Pharmacokinetic characterization. Documented the extended half-life profile of the DAC variant and interindividual variability in absorption and clearance — supporting the case for monitoring individual response rather than relying on cookie-cutter dosing.
The paper that defined Ipamorelin's selectivity. Demonstrated that it stimulates GH release without the cortisol and prolactin spikes seen with GHRP-6 and GHRP-2. This selectivity is the primary reason Ipamorelin became the preferred secretagogue for clinical stacking.
These are community-reported protocols, not clinical prescriptions. Individual response varies. Work with a provider.
If you are using this stack, these are the signals that will tell you whether it is doing anything meaningful.
Track sleep stages if you have a wearable. Deep sleep duration is the most directly GH-correlated metric.
Monthly measurements or DEXA scans. Look for trends over 3-6 months, not weekly fluctuations.
The objective biomarker. Baseline before starting, then every 6-8 weeks. Tells you if the stack is elevating GH activity.
Monitor for insulin resistance. GH can raise fasting glucose. A trend upward warrants discussion with your provider.
Log subjective bloating, morning puffiness, ring tightness. Dose-dependent and one of the earliest signals of excessive GH stimulation.
Rotate sites (abdomen, thigh, upper arm). Track any redness, lumps, or pain at injection sites.
Another GHRH analog, shorter acting than CJC-1295. FDA-approved for pediatric GH deficiency. Often used as a gentler starting point.
Oral growth hormone secretagogue. Convenient (no injection) but raises appetite significantly and has a longer side effect profile. Not a peptide — it is a small molecule.
Older GH secretagogue. More potent GH release than Ipamorelin but also raises cortisol, prolactin, and appetite. Ipamorelin was developed specifically to avoid these drawbacks.
Log every dose. Monitor your IGF-1 and sleep data. Let your own numbers tell you whether this stack is working for your body.
Get Started Free →